This federal Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $999,999,999 IDC serves as a primary vehicle for AmerisourceBergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. In addition to the DLA contract, AmerisourceBergen also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation, covering similar medical products and prescription drugs. The contract does not have any set-aside designations, indicating open competition.
The task orders issued under this IDC demonstrate the breadth of medical products delivered, including medications for conditions such as diabetes, cardiovascular health, pain management, infectious disease prevention, and general medical care. Specific task orders cover items like Ranolazine extended-release tablets, Ozempic for diabetes, Elmiron capsules, Ondansetron tablets, Epinephrine auto-injectors, and various other prescription drugs, vaccines, and medical supplies. The orders are firm fixed-price arrangements with performance periods generally running through November 2024. The place of performance for these deliveries is Conshohocken, PA.
Generated 2/27/25, 10:20 AM